A real-world analysis of trametinib in combination with hydroxychloroquine or CDK4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma

BACKGROUND: There are no standard third-line treatment options for metastatic pancreatic ductal adenocarcinoma (mPDAC). Trametinib in combination with hydroxychloroquine (HCQ) or CDK4/6 inhibitors for pancreatic adenocarcinoma showed promising efficacy in preclinical studies. However, the regimens h...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Hui, Ge, Yuping, You, Tingting, Li, Xiaoyuan, Wang, Yingyi, Cheng, Yuejuan, Bai, Chunmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563303/
https://www.ncbi.nlm.nih.gov/pubmed/37817078
http://dx.doi.org/10.1186/s12885-023-11464-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563303/
https://www.ncbi.nlm.nih.gov/pubmed/37817078
http://dx.doi.org/10.1186/s12885-023-11464-3

Ejemplares similares